13F Holdings
中文EN

REGN REGENERON PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 872589 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY5.2%
TTM EPS YoY8.4%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR6.5%

Margins

Gross margin—
Operating margin28.8%
Net margin28.5%
FCF margin22.6%
EBITDA margin31.8%

Returns

ROE14.9%
ROA11.4%
ROIC (approx.)13.2%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.06x
Current ratio3.35x
Interest coverage104.16x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio-0.1%
Payout ratio8.0%
Capex / revenue6.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$14.34B$14.20B$13.12B$12.17B$16.07B
R&D expense$5.85B$5.13B$4.44B$3.59B$2.86B
SG&A expense$2.70B$2.95B$2.63B$2.12B$1.82B
Operating income$3.58B$3.99B$4.05B$4.74B$8.95B
Interest expense$43.80M$55.20M$73.00M$59.40M$57.30M
Pretax income$5.23B$4.78B$4.20B$4.86B$9.33B
Income tax$725.80M$367.30M$245.70M$520.40M$1.25B
Net income$4.50B$4.41B$3.95B$4.34B$8.08B
EBITDA$4.12B$4.47B$4.47B$5.08B$9.23B
EPS (basic)43.0740.9037.0540.5176.40
EPS (diluted)41.4838.3434.7738.2271.97
Weighted avg. shares (diluted)108.60M115.10M113.70M113.50M112.20M
Balance sheet
Cash & equivalents$3.12B$2.49B$2.73B$3.12B$2.90B
Short-term investments$5.49B$6.52B$8.11B$4.64B$2.81B
Receivables$5.74B$6.21B$5.67B$5.33B$6.04B
Inventory$3.20B$3.09B$2.58B$2.40B$1.95B
Current assets$18.02B$18.66B$19.48B$15.88B$14.01B
PP&E, net$5.12B$4.60B$4.15B$3.76B$3.48B
Intangibles$1.26B$1.15B$1.04B$915.50M$6.70M
Total assets$40.56B$37.76B$33.08B$29.21B$25.43B
Current liabilities$4.37B$3.94B$3.42B$3.14B$3.93B
Long-term debt$1.99B$1.98B$1.98B$1.98B$1.98B
Total debt$1.99B$1.98B$1.98B$1.98B$1.98B
Total liabilities$9.30B$8.41B$7.11B$6.55B$6.67B
Shareholders' equity$31.26B$29.35B$25.97B$22.66B$18.77B
Net debt-$1.13B-$504.60M-$747.10M-$1.14B-$918.10M
Cash flow statement
Operating cash flow$4.98B$4.42B$4.59B$5.01B$7.08B
Capital expenditure$898.40M$755.90M$718.60M$590.10M$551.90M
Free cash flow$4.08B$3.66B$3.88B$4.42B$6.53B
Investing cash flow-$629.10M-$2.47B-$3.19B-$3.78B-$5.38B
Financing cash flow-$3.72B-$2.20B-$1.79B-$1.01B-$1.01B
Depreciation & amortization$543.70M$482.90M$421.00M$341.40M$286.20M
Stock-based compensation$993.70M$982.80M$885.00M$725.00M$601.70M
Dividends paid$370.30M$0$0——
Share buybacks$3.44B$2.60B$2.23B$2.08B$1.65B

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.